Proactiveinvestors Australia

SomnoMed www.somnomed.com.au/

SomnoMed Limited (ASX: SOM) specialises in products for sleep apnea and anti-snoring through its patented mandibular advancement splint, the SomnoDent MAS.    The company's SomnoDent® MAS devices and services are provided to Patients, Dentists and Sleep Specialists.

Tweet

 

Email

Email to a friend:

To:

Separate multiple addresses with commas.

From Email address:

Name: Please send me a copy Message:

Verification code

Enter the code from aboveRequired

Send

SomnoMed showcases SomnoDent sleep apnea device at SLEEP 2009

Showcasing its SomnoDent™ MAS dental sleep apnea device, SomnoMed (ASX: SOM) has participated at the Annual SLEEP 2009 exhibition in Seattle.  This is the centre point for Dental Sleep Medicine and the Sleep Medicine fraternity worldwide.

SomnoDent™ MAS was featured for a record number of American Association of Dental Sleep Medicine (AADSM) practitioners, with over 600 delegates and the medical conference of Associated Professional Sleep Societies (APSS), which attracted more than 6,000 delegates.

Exhibition activities were focused on the positioning of the SomnoDent MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing. 

The SomnoDent™ MAS dental sleep device consists of two acrylic plates fitted over the upper and low teeth. A patented fin coupling mechanism on the lower arch accurately positions the lower jaw (mandible) a little forward of its natural position.

Ralf Barschow, SomnoMed's CEO said that SLEEP 2009 was a very important strategic investment for SomnoMed and "I am very pleased with the response. It offered an ideal opportunity to present the SomnoDent™ MAS therapeutic option to a broader medical fraternity."

SomnoMed is positioning the SomnoDent™ MAS therapy as a patented, clinically proven and compliant third generation OSA treatment option for sleep disordered breathing.

Barschow said SLEEP 2009 "also confirmed our view that there is a significant demand for the SomnoDent MAS therapy for all patients diagnosed and untreated, as well as non-compliant to traditional treatment options, such as surgery or CPAP."

Sign up to Proactive Investors

Comments from Proactive Investors readers

• Fill in your details below:

Verification Code

Reload image